ItalianoISCA, CHRYSTEL
Dettaglio
ISCA, CHRYSTEL
Pubblicazioni
Risultati 1 - 15 di 15 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. | 2018 | Pozzi, S.; Belletti, L.; Cortesi, L.; Moscetti, L.; Omarini, C.; Piacentini, F.; Toss, A.; Caputo, Francesco; Greco, S.; Isca, C.; Napolitano, M.; Tarantino, V.; Malinverni, C.; Checchi, Eleonora; Mascia, Maria Teresa; Cascinu, S |
| 2 | Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. | 2019 | Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F. |
| 3 | Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials | 2020 | Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L. |
| 4 | Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. | 2019 | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F |
| 5 | Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? | 2018 | Toss, A.; Venturelli, M.; Sperduti, I.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L; Cascinu, Stefano; Moscetti, L. |
| 6 | Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial | 2019 | Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L |
| 7 | First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? | 2018 | Toss, A; Venturelli, M; Sperduti, I; Isca, C; Molinaro, E; Barbieri, E; Piacentini, F; Omarini, C; Cortesi, L; Cascinu, S; Moscetti, |
| 8 | First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? | 2018 | Toss, A.; Venturelli, Marta; Sperduti, I.; Isca, Chrystel; Barbieri, Elena; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L. |
| 9 | First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis | 2019 | Toss, A.; Venturelli, M.; Sperduti, I.; Molinaro, E.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L. |
| 10 | Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. | 2019 | Palumbo, Patrizia; Draisci, Stefano; Barbolini, Monica; Nasso, Cecilia; Isca, Chrystel; Bocconi, Alessandro; Balduzzi, Sara; Pecchi, Annarita; Galetti, Silvia; Torricelli, Pietro; Piacentini, Federico; Moscetti, Luca; Cascinu, Stefano; Omarini, Claudia |
| 11 | Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy | 2020 | Omarini, Claudia; Bettelli, Stefania Raffaella; Manfredini, Samantha; Barbolini, Monica; Isca, Chrystel; Cortesi, Giulia; Maiorana, Antonino; Tazzioli, Giovanni; Dominici, Massimo; Piacentini, Federico |
| 12 | Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. | 2019 | Omarini, C; Palumbo, P; Pecchi, A; Draisci, S; Balduzzi, S; Nasso, C; Barbolini, M; Isca, C; Bocconi, A; Moscetti, L; Galetti, S; Tazzioli, G; Torricelli, P; Cascinu, S; Piacentini, F. |
| 13 | Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. | 2020 | Nasso, C.; Barbolini, M.; Isca, C.; D'onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C. |
| 14 | PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis | 2020 | D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F. |
| 15 | Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era | 2021 | Toss, A; Isca, C; Venturelli, M; Nasso, C; Ficarra, G; Bellelli, V; Armocida, C; Barbieri, E; Cortesi, L; Moscetti, L; Piacentini, F; Omarini, C; Andreotti, A; Gambini, A; Battista, R; Dominici, M; Tazzioli, G |
Copyright © 2021